St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer

Last updated: September 28, 2021
Sponsor: Wake Forest University Health Sciences
Overall Status: Terminated

Phase

2

Condition

Breast Cancer

Cancer

Treatment

N/A

Clinical Study ID

NCT00110136
REBACCCWFU 98301
U10CA081851
  • Ages > 18
  • Female

Study Summary

RATIONALE: St. John's wort may help relieve hot flashes in women with breast cancer.

PURPOSE: This phase II trial is studying how well St. John's wort works in relieving hot flashes in women with non-metastatic breast cancer.

Eligibility Criteria

Inclusion

DISEASE CHARACTERISTICS:

  • Diagnosis of 1 of the following:
  • Noninvasive ductal carcinoma in situ
  • Localized breast cancer
  • Stage 0-IIIB disease
  • Locally recurrent breast cancer that is post-treatment AND disease-free for ≥ 2years
  • Experiencing ≥ 3 hot flashes per day (≥ 21 per week), defined by sweating, flushing,sensation of warmth, night sweats, and/or rapid heart beat of sufficient severity thatthe patient desires therapeutic intervention
  • Normal mammogram within the past 10 months
  • Hormone receptor status:
  • Not specified INCLUSION CRITERIA: Age
  • 18 and over Sex
  • Female Menopausal status
  • Post-menopausal (i.e., no menstrual periods ≥ 12 months or surgical menopause) Performance status
  • ECOG 0-2 Life expectancy
  • Not specified Hematopoietic
  • Not specified Hepatic
  • Bilirubin < 2 mg/dL
  • SGOT ≤ 2 times normal Renal
  • Not specified

Exclusion

EXCLUSION CRITERIA:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No history of intolerance to St. John's wort PRIOR CONCURRENT THERAPY: Biologic therapy
  • Not specified Chemotherapy
  • No concurrent cytotoxic chemotherapy Endocrine therapy
  • No concurrent selective estrogen-receptor modulators or aromatase inhibitors (e.g.,anastrozole, letrozole, or exemestane) allowed
  • Concurrent tamoxifen allowed
  • No concurrent estrogen, progestational agents, or androgens for the alleviation of hotflashes
  • No concurrent corticosteroids Radiotherapy
  • Not specified Surgery
  • Not specified Other
  • More than 14 days since prior Hypericum perforatum (St. John's wort), monoamineoxidase inhibitors, selective serotonin reuptake inhibitors (e.g., sertraline,paroxetine, or fluoxetine) or selective norepinephrine reuptake inhibitors (e.g.,venlafaxine)
  • No concurrent use of any of the following:
  • Antidepressants
  • Theophylline
  • Warfarin, unless for central line prophylaxis
  • Protease inhibitors for AIDS
  • Digoxin
  • Cyclosporine
  • Benzodiazepines (e.g., diazepam or alprazolam)
  • Calcium-channel blockers (e.g., diltiazem or nifedipine)
  • Coenzyme A reductase inhibitors for serum cholesterol reduction
  • Macrolide antibiotics (e.g., azithromycin, erythromycin, or clarithromycin)
  • Griseofulvin
  • Phenobarbital
  • Phenytoin
  • Rifampin
  • Rifabutin
  • Grapefruit juice
  • Other naturopathic or herbal products
  • Ketoconazole
  • Fluconazole
  • Itraconazole
  • Rifabutin
  • No other concurrent medications for the alleviation of hot flashes (e.g., clonidine orbellamine)

Study Design

Total Participants: 9
Study Start date:
March 16, 2006
Estimated Completion Date:
April 01, 2008

Study Description

OBJECTIVES:

Primary

  • Determine the efficacy of Hypericum perforatum (St. John's wort) in alleviating hot flashes, in terms of hot flash frequency, score, and duration and disruption of daily activities caused by hot flashes, in postmenopausal women with non-metastatic breast cancer.

  • Determine hot flash changes over 4 weeks in patients treated with this drug.

Secondary

  • Determine the toxicity of this drug in these patients.

  • Determine the effect of Hypericum perforatum (St. John's wort) on serum tamoxifen levels in women receiving tamoxifen therapy.

  • Determine the effect of Hypericum perforatum (St. John's wort) on general health-related quality of life and mood at 2 and 4 weeks relative to baseline, and during the 2 week post-treatment phase in these patients.

  • To evaluate changes in average weekly hot flush scores and duration over course of study.

OUTLINE: This is a multicenter study.

Patients receive oral Hypericum perforatum (St. John's wort) three times daily for 4 weeks in the absence of disease progression or unacceptable toxicity.

Patients complete a daily diary of the frequency, severity, and duration of their hot flashes, and complete quality of life and mood assessments every 2 weeks during study treatment and continuing weekly for 2 weeks after completion of study treatment.

Patients receiving tamoxifen will have blood tests to measure serum tamoxifen levels at baseline, 2, 4, and 6 weeks.

PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.

Connect with a study center

  • Helen F. Graham Cancer Center at Christiana Hospital

    Newark, Delaware 19713
    United States

    Site Not Available

  • MBCCOP - Howard University Cancer Center

    Washington, District of Columbia 20060
    United States

    Site Not Available

  • University of Miami Sylvester Comprehensive Cancer Center - Miami

    Miami, Florida 33136
    United States

    Site Not Available

  • CCOP - Central Illinois

    Decatur, Illinois 62526
    United States

    Site Not Available

  • CCOP - Northern Indiana CR Consortium

    South Bend, Indiana 46601
    United States

    Site Not Available

  • Feist-Weiller Cancer Center at Louisiana State University Health Sciences

    Shreveport, Louisiana 71130-3932
    United States

    Site Not Available

  • CCOP - Michigan Cancer Research Consortium

    Ann Arbor, Michigan 48106
    United States

    Site Not Available

  • CCOP - Beaumont

    Royal Oak, Michigan 48073-6769
    United States

    Site Not Available

  • CCOP - Metro-Minnesota

    Saint Louis Park, Minnesota 55416
    United States

    Site Not Available

  • CCOP - Metro-Minnesota

    St. Louis Park, Minnesota 55416
    United States

    Site Not Available

  • CCOP - St. Louis-Cape Girardeau

    Saint Louis, Missouri 63141
    United States

    Site Not Available

  • Cancer Research for the Ozarks

    Springfield, Missouri 65804
    United States

    Site Not Available

  • CCOP - St. Louis-Cape Girardeau

    St. Louis, Missouri 63141
    United States

    Site Not Available

  • Alamance Cancer Center at Alamance Regional Medical Center

    Burlington, North Carolina 27216
    United States

    Site Not Available

  • Hugh Chatham Memorial Hospital

    Elkin, North Carolina 28621
    United States

    Site Not Available

  • CCOP - Southeast Cancer Control Consortium

    Goldsboro, North Carolina 27534-9479
    United States

    Site Not Available

  • Leo W. Jenkins Cancer Center at ECU Medical School

    Greenville, North Carolina 27835-6028
    United States

    Site Not Available

  • Wake Forest University Comprehensive Cancer Center

    Winston-Salem, North Carolina 27157-1096
    United States

    Site Not Available

  • CCOP - Greenville

    Greenville, South Carolina 29615
    United States

    Site Not Available

  • South Carolina Cancer Specialists

    Hilton Head Island, South Carolina 29925
    United States

    Site Not Available

  • CCOP - Upstate Carolina

    Spartanburg, South Carolina 29303
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.